Odense Municipality (Danish: Odense Kommune) is a Danish municipality (kommune) in Southern Denmark on the island of Funen in central Denmark. The municipality covers an area of 304.34 km2 (118 sq mi), and has a population of 204,895 (1 January 2020). It is the most populous municipality in Region of Southern Denmark.The main town and the site of its municipal council is the city of Odense. Including the social sector, 17,000 people are employed by the municipality. The municipal budget is 6,881 million DKK as of 2006. The municipality runs 37 schools; Odense is also the home of 13 private schools.Neighboring municipalities are Kerteminde to the east, Faaborg-Midtfyn to the south, Assens to the west, and Nordfyn to the north..
Aim This review aimed to identify and synthesise existing knowledge regarding patients’ experiences of living with chronic venous leg ulcers and their encounters with healthcare systems. Materials and methods A total of 14 studies, published between 1997 and 2025, were included after a final search of PubMed, CINAHL, and Scopus databases on February 22nd, 2025, followed by screening and quality assessment using the Critical Appraisal Skills Programme. We included qualitative studies of participants aged >18 years with chronic venous leg ulcers, reporting patients' experiences of everyday life and their encounters with healthcare systems. Included studies had between 1 and 37 participants, for a total of 192 participants, with a wound duration between 2 months and 34 years. Braun & Clarke's thematic analysis was used for synthesis. Results Three main themes emerged: Challenges in everyday life with a chronic venous leg ulcer; challenges with psychosocial aspects of living with a chronic venous leg ulcer; and challenges in the patient journey. Conclusion These findings highlight how patients' daily lives are marked by reduced mobility and stigmatisation. Patients' understanding of their condition could be improved; healthcare professionals should inform patients about their condition and treatment effectiveness to increase compliance. Improved relationships between patients and healthcare professionals could enhance patients’ experiences of trust, involvement, and continuity. Health education programmes and treatment planning must focus on building relationships as part of patient journeys.
OBJECTIVES:The Bacillus Calmette-Guerin (BCG) vaccine has beneficial effects on the immune system, which may lead to non-specific protection against non-tuberculous infections and increase the response to subsequent vaccinations. Seasonal influenza vaccination is used to protect senior citizens against influenza, but the serological response to the inactivated influenza vaccine (IIV) decreases in the elderly due to immunosenescence. The aim of this study was to test the capacity of BCG to boost the specific immune response to IIV and explore the effect of BCG on the innate immune system and health of senior citizens. METHODS:A randomised controlled trial with a nested immunological study including 273 Danish citizens >65 years. Participants were randomised into four equally sized groups combining BCG with IIV in different sequences compared with IIV alone. The primary outcome was change in influenza antibody hemagglutination inhibition (HI) titre four weeks after vaccination. Secondary outcomes were infection rate during six months follow-up, and association between influenza antibody titre and infection rate. In subgroup analyses, we explored the effect of BCG on lymphocyte populations seven days after IIV and on cytokine production after stimulation of mononuclear cells in vitro. RESULTS:Four weeks after influenza vaccination, the mean fold change in HI titre over all serotypes was 2.3-2.5 with no significant differences between the treatment groups. Seroconversion rate was comparable between treatment groups, and in strata of age and sex. There was no difference in the rate of infection between the groups and there was no association with influenza antibody level. We found no difference in distribution of lymphocytes. Combining BCG with IIV had modest impact on in vitro cytokine production compared with IIV alone. CONCLUSION:BCG vaccination did not increase serological response to seasonal influenza vaccination or reduce the incidence of infection in this population of Danish senior citizens. TRIAL REGISTRATION:EU Clinical Trials Register (EudraCT number 2019-002781-12). SUMMARY:In this randomised clinical trial of Danish senior citizens, BCG vaccination did not influence serological response to influenza vaccination or reduce the risk of infection compared with placebo. There was no clear indication of induction of trained immunity.
Introduction and Objective: To determine whether impaired awareness of hypoglycemia (IAH) is associated with depression, anxiety, diabetes distress and fear of hypoglycemia in people with T1D or insulin-treated T2D. Methods: 276 T1D and 321 insulin-treated T2D participants in the Hypo-METRICS study completed questionnaires to assess for depression (PHQ-9), anxiety (GAD-7), diabetes distress (PAID) and fear of hypoglycemia (HFS-II; worry and behavior). IAH was defined as a Gold score of ≥4. Logistic regression analyses were performed to assess the cross-sectional relationships between mental health scores and IAH. Results: IAH was associated with significantly higher depression and anxiety in both groups (for depression OR 1.44 [1.26-1.64; p <0.001] in T1D, OR 1.15 [1.04-1.27; p <0.001] in T2D, for anxiety OR 1.44 [1.25-1.66; p <0.001] in T1D, OR 1.16 [1.03-1.3; p 0.013] in T2D). IAH was also associated with more worries about hypoglycemia in T1D (OR 1.29 [1.2-1.39]; p <0.001) and T2D (OR 1.27 [1.19-1.36]; p <0.001), and more diabetes distress in T1D (OR 1.35 [1.27-1.43]; p <0.001) and less diabetes distress in T2D (OR 0.92 [0.88-0.97]; p 0.002). Conclusion: IAH is significantly associated with higher levels of depression, anxiety and fear of hypoglycemia in T1D and insulin-treated T2D. Interventions that address mental health, as well as hypoglycemia risk, may be more effective at restoring awareness. A.M. McCarthy: None. P. Divilly: None. F. Pouwer: Research Support; Novo Nordisk, Eli Lilly and Company. P. Choudhary: Speaker's Bureau; Abbott. Advisory Panel; Dexcom, Inc. Consultant; Insulet Corporation. Advisory Panel; Ypsomed AG, embecta, Sanofi. Speaker's Bureau; Lilly Diabetes, Medtronic. Advisory Panel; Roche Diabetes Care. Consultant; Cambridge Mechatronics.